Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Recurrence 1Neoplasms 1Ependymoma 1Disease Progression 1Diffuse Intrinsic Pontine Glioma 1

Interventions

umbralisib 1ublituximab 1marizomib 1fludarabine phosphate 1fludarabine 1enzastaurin 1durvalumab 1carotuximab 1brigatinib 1binimetinib 1axicabtagene ciloleucel 1Zoledronic Acid 1Vitamin D 1Receptors, Interleukin-6 1Oxaliplatin 1Leucovorin 1Irinotecan 1Interleukin 1 Receptor Antagonist Protein 1Gemcitabine 1Folfox protocol 1Fluorouracil 1Cyclophosphamide 1Cisplatin 1Calcium 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Disease Progression × marizomib × Clear all
NCT03727841 2022-07-27

Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
4 enrolled 13 charts

Ependymoma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡